![](/img/cover-not-exists.png)
Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
Adriana Martin, Robert SchellenbergVolume:
8
Language:
english
DOI:
10.1186/1710-1492-8-S1-A19
Date:
November, 2012
File:
PDF, 68 KB
english, 2012